- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Interventions
- Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
- Radiation · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 377
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more
Location Directory
Clinical trials in Tampa, Florida
This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9115
Shown on this page
12
Current sort
Recently updated
Location scope
Tampa, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 277–288 of 9,115 matching trials in Tampa, FL.
Live ClinicalTrials.gov results.
Institutions in Tampa
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Not listed
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 9
- States / cities
- Stanford, California • Tampa, Florida • Boston, Massachusetts + 6 more
- Conditions
- Moderate to Severe Chronic Obstructive Pulmonary Disease
- Interventions
- PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 50 more
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Interventions
- LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
- Conditions
- Epilepsy, Epilepsy (Treatment Refractory)
- Interventions
- Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Device
- Lead sponsor
- Epiminder America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 16 more
- Conditions
- PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer
- Interventions
- CGT6297
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 9 more
- Conditions
- Alzheimer Disease
- Interventions
- ONO-2020, Placebo
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 53 more
- Conditions
- Peripheral Artery Disease (PAD)
- Interventions
- REGN7508, REGN9933, Placebo, Rivaroxaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 27
- States / cities
- Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 1,673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 928
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
- Conditions
- Dry Eye Disease (DED)
- Interventions
- DFL24498, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Azusa, California • Glendale, California + 21 more
- Conditions
- Renal Impairment
- Interventions
- S-892216-PO
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Orlando, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more
- Conditions
- SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
- Interventions
- Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more